Lamivir

Lamivir is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. The recommended oral dose of Lamivir in HIV-1 infected adults and adolescents >16 years of age is 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily, in combination with other antiretroviral agents. If Lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen. The recommended oral dose of Lamivir in HIV-1 infected pediatric patients, 3 months to 16 years of age, is 4 mg/kg twice daily (up to a maximum of 150 mg twice a day), administered in combination with other antiretroviral agents. Lamivir can cause life-threatening inflammation of the pancreas (pancreatitis). This can be very dangerous. Let your healthcare provider know immediately if you have any signs of pancreatitis, such as: a tender or swollen abdomen; nausea and vomiting ; fever: rapid heart rate (tachycardia): rapid breathing. Lamivir can rarely cause a condition called lactic acidosis and hepatic steatosis. It is caused by damage to the liver and can be very dangerous. You are at higher risk for this side effect if you already have liver disease. The kidneys help remove Lamivir from the body. If you have kidney disease, your healthcare provider may need to monitor you more closely and may recommend a lower lamivudine dosage. Lamivir can change the distribution of fat on your body. You may gain fat in areas that are not typical for you, such as in the abdomen or at the back of the neck (a "buffalo hump"), and may lose weight in other areas.